文献速递神经肿瘤小儿神经外科与脑积水

加拿大36个月以下儿童胚胎性肿瘤:加拿大儿童脑肿瘤联盟(CPBTC)研究结果

Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC).
PubMed 文献 · J Neurooncol · 2017-05-16

该观察性研究纳入加拿大1990至2005年诊断的所有36个月以下中枢神经系统肿瘤患者,胚胎性肿瘤占全部中枢神经系统肿瘤的26.9%,其中髓母细胞瘤占61.5%、非典型畸胎样/横纹肌样瘤(AT/RT)占18%、原始神经外胚层肿瘤(PNET)占16%。加拿大髓母细胞瘤、PNET和AT/RT的18个月生存率分别为0.74、0.64和0.36,24个月生存率分别为0.68、0.60和0.29,数据与已发表的国际率相当。

要点

  • 胚胎性肿瘤占36个月以下中枢神经系统肿瘤的26.9%,髓母细胞瘤占61.5%。
  • AT/RT和PNET在更小年龄组更常见,髓母细胞瘤在25至36个月年龄组患病率最高。
  • 髓母细胞瘤18和24个月生存率分别为0.74和0.68。

核心结论

  • 加拿大胚胎性肿瘤的发病率和结局数据与已发表的国际率相当,可指导未来对这些罕见肿瘤的研究。

研究设计与样本

  • 观察性研究,回顾加拿大1990至2005年诊断的所有36个月以下中枢神经系统肿瘤患者。
  • 纳入加拿大儿童脑肿瘤联盟(CPBTC)的多机构数据。

主要发现

  • 胚胎性肿瘤占全部中枢神经系统肿瘤的26.9%。
  • 髓母细胞瘤占胚胎性肿瘤的61.5%,AT/RT占18%,PNET占16%,先天性髓上皮瘤占2.6%,室管膜母细胞瘤占1.9%。
  • AT/RT和PNET在更小年龄组更常见,髓母细胞瘤在25至36个月年龄组患病率最高。
  • 髓母细胞瘤18和24个月生存率分别为0.74和0.68,PNET分别为0.64和0.60,AT/RT分别为0.36和0.29。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Embryonal tumors are a heterogeneous group of central nervous system (CNS) tumors whose subgroups have varying incidence and outcome. Despite these differences, they are often grouped as a single entity for study purposes. To date, there are no Canadian multi-institutional studies examining the incidence and outcome of all embryonal subtypes. The current study is an observational study reviewing embryonal tumors in all patients less than 36 months of age diagnosed with a CNS tumor in Canada from 1990 to 2005. Embryonal tumors accounted for 26.9% of all CNS tumors. Medulloblastomas were the highest proportion of the embryonal tumors at 61.5%. Atypical teratoid/rhabdoid tumors (AT/RT) had the second highest proportion of embryonal tumors at 18%. The proportion of primitive neuroectodermal tumors (PNET) was 16%, with 2.6 and 1.9% for congenital medulloepithelioma and ependymoblastoma tumors, respectively. AT/RT and PNET were more common in younger age groups. Medulloblastoma became more prevalent with increasing age, with its highest prevalence in the 25 to 36 month age group. Survival rates for our Canadian population at 18 and 24 months were 0.74 and 0.68 for medulloblastoma, 0.64 and 0.60 for PNET, and 0.36 and 0.29 for AT/RT, respectively. Overall, our data are comparable with published international rates for embryonal tumors. These incidence and outcome figures can guide future research into these rare tumors.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Story E, Johnston DL, Bartels U, et al. Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC). J Neurooncol. 2017. PMID: 28508928. doi:10.1007/s11060-017-2468-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。